Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,914 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06939127RecruitingPhase 2
Cold therapy, immunotherapy, and chemo before and after lung cancer surgery
This trial tests a treatment that uses extreme cold (cryoablation) along with immunotherapy (tislelizumab) and chemotherapy before and after surgery for people with early-stage lung cancer that can be removed. The goal is to see if this combination helps prevent the cancer from coming back.
TianjinAges 18–75 - NCT06940388RecruitingPhase 2
Immunotherapy plus standard treatment for rectal cancer
This trial is testing whether adding the immunotherapy drug tislelizumab to standard total neoadjuvant treatment (chemotherapy and radiation before surgery) can improve outcomes for people with locally advanced rectal cancer. The goal is to see if the combination helps shrink the tumor more than standard treatment alone.
MainzAges 18 years+ - NCT06940440RecruitingPhase 1
IFx-Hu2.0 with pembrolizumab for advanced Merkel cell carcinoma
This trial tests a new drug, IFx-Hu2.0, given alongside the immunotherapy pembrolizumab (Keytruda) for people with advanced or spreading Merkel cell carcinoma (MCC). The goal is to see if the combination helps shrink tumors and slow the disease.
Tampa, FloridaAges 18 years+ - NCT06944262Recruiting
Cancer-related stress study for patients and caregivers
This study looks at stress after a cancer diagnosis and asks patients and caregivers what kind of support they want. It may help improve care for people coping with cancer.
Lille, NordAges 18 years+ - NCT06947928RecruitingPhase 2/Phase 3
Vaccine plus immunotherapy for Merkel cell cancer
This trial tests an experimental vaccine (IFx-Hu2.0) followed by the immunotherapy drug pembrolizumab in people with advanced Merkel cell carcinoma who have not been treated with checkpoint inhibitors before. The goal is to see if this combination helps shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06950073Recruiting
Second radiation treatment for lung cancer in the chest
This study tests whether giving a second course of radiation to the chest (called retreatment) can control lung cancer that has come back or a new cancer that started there. People who have already had radiation to their chest and are healthy enough for more may be eligible.
Aarhus, JutlandAges Any age - NCT06954584RecruitingPhase 3
Fluzoparib with or without bevacizumab or diet for advanced ovarian cancer
This trial tests if adding bevacizumab (a drug that blocks blood vessel growth) or a special diet to fluzoparib (a PARP inhibitor) works better than fluzoparib alone for women with advanced ovarian cancer whose tumors have specific genetic features (HRD-positive or HRD-negative). It is for patients who have already responded well to initial chemotherapy.
Wuhan, HubeiAges 18 years+ - NCT06954623Recruiting
Partial breast re-irradiation for breast cancer recurrence
This trial tests a second round of radiation to just part of the breast for women who had a previous lumpectomy and radiation, and now have a small, early-stage cancer or DCIS in the same breast. The goal is to see if a focused re-treatment is safe and effective.
HeidelbergAges 18 years+ - NCT06959810Recruiting
Aesthetic support for head and neck cancer patients
This study looks at whether a special program focused on how you look and feel (aesthetic oncology) can help people with head and neck cancers during their treatment. You may qualify if you are getting treatment to try to cure your cancer and can speak French.
CaenAges 18 years+ - NCT06961955RecruitingPhase 2
Shorter versus longer whole breast radiation for early-stage breast cancer
This trial compares a 5-day course of whole breast radiation plus a boost to the standard 9-day course for people with early-stage breast cancer who have certain risk factors, such as high-grade tumors or younger age. The goal is to see if the shorter treatment is just as safe and effective.
Salt Lake City, UtahAges 18 years+ - NCT06972602RecruitingEarly Phase 1
High-dose topotecan for retinoblastoma with vitreous seeds
This trial tests a high dose of a chemotherapy drug called topotecan given directly into the eye (intravitreal injection) for children with retinoblastoma that has come back or not responded to treatment and has seeds floating in the vitreous. The goal is to save the eye when removal is the only other option.
Shanghai, ChinaAges 1–12 - NCT06975410RecruitingPhase 1/Phase 2
Trial of YH32364 for EGFR-positive solid tumors
This trial tests a new drug, YH32364, for people with advanced solid tumors that have high levels of EGFR protein. It looks at whether the drug can help when standard treatments have stopped working.
SeoulAges 18 years+ - NCT06987734RecruitingPhase 2
Sugemalimab plus chemo before and after lung cancer surgery
This trial tests if adding the immunotherapy drug sugemalimab to standard chemotherapy before and after surgery can help people with stage II-IIIA non-small cell lung cancer. It aims to see if this combination reduces the chance of cancer coming back.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06990880RecruitingPhase 1/Phase 2
Study of GSK5458514 alone or with other drugs for prostate cancer
This trial tests a new drug, GSK5458514, either alone or with other cancer treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if the drug can slow down the cancer.
Phoenix, ArizonaAges 18 years+ - NCT07003100Recruiting
Studying mogamulizumab rash in mycosis fungoides or sezary syndrome
This study looks at a common skin rash caused by the drug mogamulizumab in patients with certain types of lymphoma. It aims to learn more about the rash and how to manage it, so your experience can help future patients.
Duarte, CaliforniaAges 18 years+ - NCT07010263RecruitingPhase 3
AK112 for limited-stage small cell lung cancer after chemoradiation
This study tests a new drug called AK112 (a bispecific antibody that blocks both PD-1 and VEGF) as a consolidation treatment to help prevent your limited-stage small cell lung cancer from coming back after you've finished chemoradiation. It's for people whose cancer has not grown following concurrent chemotherapy and radiation.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07017673RecruitingPhase 2
Ivonescimab with chemo for early-stage triple negative breast cancer
This trial tests a new drug, ivonescimab, combined with standard chemotherapy before surgery for people with high-risk early-stage triple negative breast cancer. The goal is to see if adding this drug improves treatment response.
Los Angeles, CaliforniaAges 18 years+ - NCT07019220RecruitingPhase 2
Chemoablation for low-risk bladder cancer
This trial tests using chemotherapy directly into the bladder to treat low-grade bladder cancer that has come back, as an alternative to surgery. It may help people with small, low-grade tumors avoid the need for a more invasive procedure.
ViennaAges 18 years+ - NCT07036731Recruiting
Urine test study for second bladder surgery
This trial compares the need for a second surgery for people with early-stage bladder cancer. It uses a simple urine test to see if the test can help decide whether a second operation is necessary, which could save some patients from an extra procedure.
Nanjing, JiangsuAges 18–80 - NCT07037199RecruitingPhase 2
A new drug combo for HR+ advanced breast cancer
This trial tests a sequence of three drugs: first trastuzumab rezetecan (a targeted therapy), then a CDK4/6 inhibitor plus hormone therapy. It's for people with a type of breast cancer called HR-positive, HER2-low or ultra-low that has spread or come back and has already progressed on a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18 years+ - NCT07051083Recruiting
Bladder cancer staging trial using AI on imaging scans
This trial uses artificial intelligence to look at ultrasound and other scans to better stage bladder cancer and predict if chemotherapy before surgery might work. It may help doctors plan your treatment more precisely.
Guangzhou, GuangdongAges Any age - NCT07056010Recruiting
Minimally invasive surgery for advanced stomach cancer after chemoimmunotherapy
This trial tests a minimally invasive surgery for stomach cancer that has spread to lymph nodes near the main blood vessels (para-aortic area). The surgery is done after a combination of chemotherapy and immunotherapy to shrink the tumor. It aims to see if this approach is safe and effective.
Nanjing, JiangsuAges 18–80 - NCT07065630RecruitingPhase 2
New immunotherapy for HPV-negative head and neck cancer
This trial tests a new immunotherapy drug called volrustomig for people with advanced head and neck cancer that is not caused by HPV. The goal is to see if giving this treatment based on how the cancer responds can help shrink tumors or stop them from growing.
Chicago, IllinoisAges 18 years+ - NCT07066098RecruitingPhase 3
New drug IBI343 for advanced pancreatic cancer with CLDN18.2 protein
This study tests a new drug called IBI343 compared to a placebo (inactive substance) for people with advanced pancreatic cancer that has a specific protein (CLDN18.2) and has not responded to earlier treatments. The goal is to see if IBI343 can help slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,914 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.